Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$206K Buy
737
+23
+3% +$6.52K 0.04% 108
2025
Q1
$222K Buy
+714
New +$211K 0.05% 87
2024
Q4
Sell
-861
Closed -$277K 89
2024
Q3
$277K Sell
861
-142
-14% -$46.4K 0.05% 84
2024
Q2
$313K Sell
1,003
-63
-6% -$18.5K 0.06% 80
2024
Q1
$303K Buy
1,066
+212
+25% +$62K 0.06% 81
2023
Q4
$246K Sell
854
-222
-21% -$60.5K 0.05% 91
2023
Q3
$289K Buy
1,076
+8
+0.7% +$2K 0.07% 76
2023
Q2
$237K Buy
1,068
+167
+19% +$38.8K 0.06% 104
2023
Q1
$218K Buy
901
+49
+6% +$12K 0.05% 104
2022
Q4
$224K Buy
+852
New +$228K 0.06% 93

Other funds holding AMGN

NBW Capital's AMGN Position: Q2 2025 in Review

NBW Capital increased its Amgen (AMGN) stake by 3.2% in Q2 2025, buying an estimated $6.52K and bringing the position to 737 shares worth $206K. The position accounts for 0.04% of the portfolio, ranked #108.

NBW Capital first reported a position in AMGN in Q4 2022 and has held it in 10 quarters since. The position peaked at $313K in Q2 2024. 2,852 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • NBW Capital held 737 shares of Amgen worth $206K as of Q2 2025.
  • NBW Capital bought 23 Amgen shares in Q2 2025, an estimated $6.52K.
  • Amgen made up 0.04% of NBW Capital's portfolio in Q2 2025, its #108 holding.
  • NBW Capital first reported a position in Amgen in Q4 2022 and has held it in 10 quarters since.
  • NBW Capital's Amgen position peaked at $313K in Q2 2024.
  • 2,852 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on NBW Capital's 13F filing for Q2 2025, filed 13 Aug 2025.